Physician profile
Michael P Doyle
NPI 1639316607
$326.87
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $311 · 2022: $15.90.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Misonix INC | $173.17 | 2021 | |
| Smith+Nephew, INC. | $35.20 | 2021 | |
| Paratek Pharmaceuticals, INC. | $22.00 | 2021 | |
| Tactile Systems Technology INC | $19.09 | 2021 | |
| Novartis Pharmaceuticals Corporation | $17.65 | 2021 | |
| Boston Scientific Corporation | $16.31 | 2021 | |
| Horizon Therapeutics Plc | $16.10 | 2021 | |
| Bioventus LLC | $15.90 | 2022 | |
| Sanofi Pasteur INC. | $11.45 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Doyle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.